Yu-Hsiang Wu

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Yu-Hsiang Wu sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials 1 currently recruiting 3 completed upper quartile by trial count

Yu-Hsiang Wu: 4 sponsored US clinical trials, 1 recruiting.

Yu-Hsiang Wu sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. The most-studied condition in this pipeline is Alzheimer Disease 2 Due to Apoe4 Isoform, with 1 trials.

Upper-quartile sponsor footprint

Yu-Hsiang Wu sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Yu-Hsiang Wu pipeline

1 recruiting of 4 indexed (25% open); 3 completed (75%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Alzheimer Disease 2 Due to Apoe4 Isoform (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Yu-Hsiang Wu: open-pipeline peers nationwide

Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

Yu-Hsiang Wu sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3456789 0%20%40%60%80% Total trials Recruiting share Yu-Hsiang Wu4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action LabAB ScienceAbbott Point of CareAccutar BiotechnologyAdrienne G. Waks
Yu-Hsiang Wu sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Yu-Hsiang Wu sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

What to do with this Yu-Hsiang Wu page

4 registered trials is a research-attention snapshot, not an endorsement of Yu-Hsiang Wu or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Yu-Hsiang Wu pipeline card: 4 registered trials from official public datasets.Report a data error.